226 related articles for article (PubMed ID: 30724342)
1. Pediatric malignancies in neurofibromatosis type 1: A population-based cohort study.
Peltonen S; Kallionpää RA; Rantanen M; Uusitalo E; Lähteenmäki PM; Pöyhönen M; Pitkäniemi J; Peltonen J
Int J Cancer; 2019 Dec; 145(11):2926-2932. PubMed ID: 30724342
[TBL] [Abstract][Full Text] [Related]
2. Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1.
Uusitalo E; Rantanen M; Kallionpää RA; Pöyhönen M; Leppävirta J; Ylä-Outinen H; Riccardi VM; Pukkala E; Pitkäniemi J; Peltonen S; Peltonen J
J Clin Oncol; 2016 Jun; 34(17):1978-86. PubMed ID: 26926675
[TBL] [Abstract][Full Text] [Related]
3. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
4. Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France.
Duong TA; Sbidian E; Valeyrie-Allanore L; Vialette C; Ferkal S; Hadj-Rabia S; Glorion C; Lyonnet S; Zerah M; Kemlin I; Rodriguez D; Bastuji-Garin S; Wolkenstein P
Orphanet J Rare Dis; 2011 May; 6():18. PubMed ID: 21542925
[TBL] [Abstract][Full Text] [Related]
5. Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1.
McCaughan JA; Holloway SM; Davidson R; Lam WW
J Med Genet; 2007 Jul; 44(7):463-6. PubMed ID: 17327286
[TBL] [Abstract][Full Text] [Related]
6. Malignant peripheral nerve sheath tumor with and without neurofibromatosis type 1.
Vasconcelos RAT; Coscarelli PG; Alvarenga RP; Acioly MA
Arq Neuropsiquiatr; 2017 Jun; 75(6):366-371. PubMed ID: 28658406
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients.
Guillamo JS; Créange A; Kalifa C; Grill J; Rodriguez D; Doz F; Barbarot S; Zerah M; Sanson M; Bastuji-Garin S; Wolkenstein P;
Brain; 2003 Jan; 126(Pt 1):152-60. PubMed ID: 12477702
[TBL] [Abstract][Full Text] [Related]
8. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis type 1 and childhood cancer.
Matsui I; Tanimura M; Kobayashi N; Sawada T; Nagahara N; Akatsuka J
Cancer; 1993 Nov; 72(9):2746-54. PubMed ID: 8402499
[TBL] [Abstract][Full Text] [Related]
10. Neurofibromatosis type 1 and malignancy in childhood.
Varan A; Şen H; Aydın B; Yalçın B; Kutluk T; Akyüz C
Clin Genet; 2016 Mar; 89(3):341-5. PubMed ID: 26073032
[TBL] [Abstract][Full Text] [Related]
11. Optical coherence tomography in the evaluation of neurofibromatosis type-1 subjects with optic pathway gliomas.
Chang L; El-Dairi MA; Frempong TA; Burner EL; Bhatti MT; Young TL; Leigh F
J AAPOS; 2010 Dec; 14(6):511-7. PubMed ID: 21168074
[TBL] [Abstract][Full Text] [Related]
12. Neurofibromatosis type 1 and sporadic optic gliomas.
Singhal S; Birch JM; Kerr B; Lashford L; Evans DG
Arch Dis Child; 2002 Jul; 87(1):65-70. PubMed ID: 12089128
[TBL] [Abstract][Full Text] [Related]
13. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
14. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1.
Evans DGR; Salvador H; Chang VY; Erez A; Voss SD; Schneider KW; Scott HS; Plon SE; Tabori U
Clin Cancer Res; 2017 Jun; 23(12):e46-e53. PubMed ID: 28620004
[TBL] [Abstract][Full Text] [Related]
15. Survival meta-analyses for >1800 malignant peripheral nerve sheath tumor patients with and without neurofibromatosis type 1.
Kolberg M; Høland M; Agesen TH; Brekke HR; Liestøl K; Hall KS; Mertens F; Picci P; Smeland S; Lothe RA
Neuro Oncol; 2013 Feb; 15(2):135-47. PubMed ID: 23161774
[TBL] [Abstract][Full Text] [Related]
16. The role of magnetic resonance imaging in the diagnostic evaluation of malignant peripheral nerve sheath tumors.
Chhabra A; Soldatos T; Durand DJ; Carrino JA; McCarthy EF; Belzberg AJ
Indian J Cancer; 2011; 48(3):328-34. PubMed ID: 21921333
[TBL] [Abstract][Full Text] [Related]
17. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1.
Dunn GP; Spiliopoulos K; Plotkin SR; Hornicek FJ; Harmon DC; Delaney TF; Williams Z
J Neurosurg; 2013 Jan; 118(1):142-8. PubMed ID: 23101443
[TBL] [Abstract][Full Text] [Related]
18. Vascular endothelial growth factor, basic fibroblast growth factor and epithelial growth factor receptor in peripheral nerve sheath tumors of neurofibromatosis type 1.
Friedrich RE; Beer C; Glatzel M; Hagel C
Anticancer Res; 2015 Jan; 35(1):137-44. PubMed ID: 25550544
[TBL] [Abstract][Full Text] [Related]
19. Survival outcomes of malignant peripheral nerve sheath tumors (MPNSTs) with and without neurofibromatosis type I (NF1): a meta-analysis.
Lim Z; Gu TY; Tai BC; Puhaindran ME
World J Surg Oncol; 2024 Jan; 22(1):14. PubMed ID: 38191386
[TBL] [Abstract][Full Text] [Related]
20. Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: A nationwide cohort study.
Martin E; Coert JH; Flucke UE; Slooff WM; van de Sande MAJ; van Noesel MM; Grünhagen DJ; Wijnen MHWA; Verhoef C
Pediatr Blood Cancer; 2020 Apr; 67(4):e28138. PubMed ID: 31889416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
